SEC Tracker
Get the app

Possible new IRLA shares

IRLADilution

Last raise Oct 17, 2025, 424B5: Up to $75.0M of shares at the market; before two reverse splits, 1-for-10 by May 4, 2026 and 1-for-20 by Aug 7, 2026

Known so far: no new shares beyond today's 1.0M · shelf room about $21.3M · not yet read: warrants, converts, options, ATM.

Shelf room

  • Room today about $21.3M
  • One third of float $21.3M ($64.0M float, Jun 30, 2025)
  • Sold off it, 12 months nothing
How this is worked out

Shelf room about $21.3M on the S-3 of Aug 5, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $64.0M public float stated as of Jun 30, 2025, $21.3M, nothing sold off it in the last 12 months. Sources: S-3/A Aug 5, 2026, effective Aug 24, 2026 · public float, as of Jun 30, 2025.

86.7K registered for resale, already counted in today's shares where issued; all likely already outstanding.

  • 17.3M shares registered for resale (86.7K after two reverse splits, 1-for-10 by May 4, 2026 and 1-for-20 by Aug 7, 2026; 8.5% of today's 1.0M) under the S-3 of Jul 25, 2025, newest prospectus the 424B5 of Aug 5, 2025; likely already outstanding

What could become new IRulya Therapeutics (IRLA) shares, from the S-3 and 424B prospectus covers we have read. Shares registered for resale are kept out of the total: where already issued, they are in today's share count.

Read so far: the cover share count (1M shares, +279% from 269K on Aug 5, 2025, adjusted for two reverse splits, 1-for-10 by May 4, 2026 and 1-for-20 by Aug 7, 2026) and the prospectus covers below. Not read yet: warrants, convertible notes, options and RSUs and an ATM program. Read them on EDGAR: the latest 10-Q · S-3 shelf filings.

Shares outstanding

1.0M

Nov 2024 to Aug 2026: from 220K to 1.0M. Adjusted for two reverse splits, 1-for-10 by May 4, 2026 and 1-for-20 by Aug 7, 2026: each earlier count is divided by the ratio of every split after it.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.